Shengbai decoction enhances the anti-tumor efficacy of cyclophosphamide on hepatoma 22-bearing mice - 17/06/21
pages | 10 |
Iconographies | 11 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Combination therapies with chemotherapy and traditional Chinese medicines are attracted increasing attentions for cancer treatment in China. Shengbai decoction (SBD) is a traditional Chinese compound medicine, composed of 6 traditional Chinese herbs. The aim of this study was to investigate the synergistic anti-tumor activity of SBD with cyclophosphamide (CTX) and the possibly underlying mechanisms in treating the hepatoma 22 (H22) -bearing mice. The liver cancer models in C57BL/6 mice were established by injecting with mouse H22 cancer cells. Results showed that combination treatment with SBD and CTX processed a significantly synergistic anti-tumor effect in H22 tumor-bearing mice. Moreover, SBD could not only improve leukopenia caused by CTX, but prolong the survival time of the mice. Furthermore, SBD could upregulate the expressions of the pro-apoptotic genes, including p53, BAD, Cas3 and Bax, and suppress the expression of anti-apoptotic gene Bcl-2. These results suggested that the combination treatment with SBD and CTX had health improving function and less side effects compared with the administration of CTX alone, and SBD could be a promising adjunct agent for liver cancer chemotherapy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Shengbai decoction (SBD) combined with cyclophosphamide (CTX) has synergistic anti-tumor effect on hepatoma 22-bearing mice. |
• | SBD could reverse the toxicity of CTX, including the increasing in WBCs, RBCs, PLTs, and the body weight of tumor bearing mice. |
• | SBD could alleviate the indexes of liver, kidney, thymus and splenic, and the inflammatory reaction indicators. |
• | SBD may enhance the anti-tumor activity by promoting apoptosis. |
Keywords : Shengbai decoction, Cyclophosphamide, Synergistic anti-tumor, Hepatoma, Apoptosis
Plan
Vol 140
Article 111775- août 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?